ANXA1 and colorectal carcinoma: Considering that DCs contribute to metastatic spread by CD8+T cell responses and Treg activity regulation, ANXA1 can be considered a prognostic indicator of CRC metastasis and a possible target for immunomodulatory therapies [128,150].